Paraoxonase activity in glomerulonephritic patients

Renal Failure

Volumn 29, Issue 4, 2007, Pages 433-439

  Gullulu, Mustafa ^a   Kahvecioglu, Serdar ^a   Dirican, Melahat ^a   Akdag, Ibrahim ^a   Ocak, Nihal ^a   Demircan, Celalettin ^a   Dilek, Kamil ^a   Ersoy, Alpaslan ^a   Yavuz, Mahmut ^a   Yurtkuran, Mustafa ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Glomerulonephritis; Lipid; Oxidation; Paraoxonase; Urinary paraoxonase

Indexed keywords

ALBUMIN; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; CREATININE; HEMOGLOBIN; LIPID; UREA; URIC ACID;

ADULT; ARTICLE; BIOPSY; CARDIOVASCULAR RISK; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; GLOMERULONEPHRITIS; GLOMERULOSCLEROSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY DISEASE; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE; UREA BLOOD LEVEL;

ADULT; APOLIPOPROTEINS B; ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; CREATININE; FEMALE; GLOMERULONEPHRITIS; HUMANS; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATION-REDUCTION; UREA;

EID: 34248512653     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220701278216     Document Type: Article

References (20)

1. Wheeler DC. Cardiovascular disease in patients with chronic renal failure. Lancet 1996;348:1673-1674.
2. Appel G. Lipid abnormalities in renal disease. Kidney Int. 1991;39:169-183.
3. Fornasieri A, Perugini C, Seccia M, Napodano P, D'Amico G, Bellomo G. Circulating antibodies recognising oxidatively-modified low-density lipoproteins in patients with IgA nephropathy, membranous glomerulonephritis and focal glomerulosclerosis. J Nephrol. 2002;15:349-357.
4. Wheeler DC, Chana RS. Interactions between lipoproteins, glomerular cells and matrix. Miner Electrolyte Metab. 1993;19:149-164.
5. Rodrigo L, Gil F, Hernandez AF, Pla A. Identification of two rat liver proteins with paraoxonase activity: biochemical evidence for the identity of paraoxonase and arylesterase. Chem Biol Interact. 1999;14:263-275.
6. Serrato M, Marian AJ. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest. 1995;96:3005-3008.
7. Schiavon R, Battaglia P, De Fanti E et al. HDL3-related decreased serum paraoxonase (PON) activity in uremic patients: comparison with the PON1 allele polymorphism. Clin Chim Acta. 2002;324:39-44.
8. Fuhrman B, Volkova N, Aviram M. Oxidative stress increases the expression of the CD36 scavenger receptor and the cellular uptake of oxidized low-density lipoprotein in macrophages from atherosclerotic mice: protective role of antioxidants and of paraoxonase. Atherosclerosis. 2002;161:307-316.
9. Dirican M, Akca R, Sarandol E, Dilek K. Serum paraoxonase activity in uremic predialysis and hemodialysis patients. J Nephrol. 2004;17:813-818.
10. Suehiro T, Ikeda Y, Shiinoki T, Inoue M, Kumon Y, Itahara T, Hashimoto K. Serum paraoxonase (PON1) concentration in patients undergoing hemodialysis. J Atheroscler Thromb. 2002;9:133-138.
11. Friedewald WT, Levy RI, Fredrickson DS. Estimation of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-508.
12. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/ arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet. 1993;52:598-608.
13. Ak G, Ozgonul M, Sozmen EY, Aslan SL, Sozmen B. Renal cortical thickness and PON1 activity both decrease in chronic renal failure. J Nephrol. 2002;15:144-149.
14. Dantoine TF, Debord J, Charmes JP, Merle L, Marquet P, Lachatre G, Leroux-Robert C. Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol. 1998;9:2082-2088.
15. Paragh G, Asztalos L, Seres I, Balogh Z, Locsey L, Karpati I, Matyus J, Katona E, Harangi M, Kakuk G. Serum paraoxonase activity changes in uremic and kidney-transplanted patients. Nephron. 1999;83:126-131.
16. Amann K, Ritz C, Adamczak M, Ritz E. Why is coronary heart disease of uraemic patients so frequent and so devastating? Nephrol Dial Transplant. 2003;18:631-640.
17. Lee HS. Oxidized LDL, glomerular mesangial cells and collagen. Diabetes Res Clin Pract. 1999;45:117-122.
18. Keane WF, Kasiske BL, O'Donnell MP. Hyperlipidemia and the progression of renal disease. Am. J Clin Nutr. 1988;47:157-160.
19. Shih DM, Gu L, Xia Y-R, Navab M, Li W-F, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998;394:284-287.
20. Navab M, Hama-Levy S, Van Lenten BJ et al. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest. 1997;99:2005-2019.